Advanced Therapeutic Interventions Targeting Mycobacterium Tuberculosis.

Q3 Veterinary
A A Razzak Mahmood, V I Rani, P Yadav, S S Patil
{"title":"Advanced Therapeutic Interventions Targeting <i>Mycobacterium Tuberculosis</i>.","authors":"A A Razzak Mahmood, V I Rani, P Yadav, S S Patil","doi":"10.32592/ARI.2025.80.1.19","DOIUrl":null,"url":null,"abstract":"<p><p>Tuberculosis infection (TBI), caused by <i>Mycobacterium tuberculosis</i> (<i>M.tb</i>), presents with or without clinical signs of active TB and is a persistent global threat despite efforts to eradicate it. The emergence of HIV/AIDS is one of the problems to complete eradication. Recent research has focused on vaccines, diagnostics, and treatment. This review examines vulnerable populations, high-risk groups, and socio-economic factors influencing TBI prevalence. It also explores the intersection of TBI and the COVID-19 pandemic, including healthcare disruptions and transmission dynamics. Advances in TBI diagnosis, biomarkers, prophylactic therapies, and combination treatments are discussed, along with the integration of artificial intelligence (AI) in TBI therapy to optimize treatment and personalize care. Vulnerability to TBI varies based on age, socio-economic status, and immune status. High-risk groups include those with compromised immune systems, the elderly, and those in crowded or poorly ventilated settings. Socioeconomic factors such as poverty and limited healthcare access also contribute to TBI prevalence. The COVID-19 pandemic has disrupted TBI diagnosis and treatment, with limited healthcare access impacting outcomes. Changes in healthcare delivery, like telemedicine, may have long-term impacts on TBI care. Improved biomarkers, like interferon-gamma release assays (IGRAs), offer faster TBI diagnosis. Prophylactic therapies, such as isoniazid preventive therapy (IPT), reduce active TB risk in high-risk groups. Combination treatments are being evaluated for drug-resistant strains. AI integration in TBI therapy could lead to better outcomes by analyzing patient data for personalized treatment plans. In conclusion, TBI remains a global health threat requiring ongoing research and innovative approaches for diagnosis and treatment. Advances in diagnosis, prophylactic therapies, and combination treatments, along with AI integration, offer hope for improved outcomes and better patient care, In conclusion, traumatic brain injury (TBI) persists as a significant global health concern, necessitating sustained research efforts and the development of innovative diagnostic and therapeutic approaches. Advancements in diagnostic methods, prophylactic therapies, combination treatments, and the integration of artificial intelligence hold promise for enhancing outcomes and enhancing patient care.</p>","PeriodicalId":8311,"journal":{"name":"Archives of Razi Institute","volume":"80 1","pages":"19-35"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426472/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Razi Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32592/ARI.2025.80.1.19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Veterinary","Score":null,"Total":0}
引用次数: 0

Abstract

Tuberculosis infection (TBI), caused by Mycobacterium tuberculosis (M.tb), presents with or without clinical signs of active TB and is a persistent global threat despite efforts to eradicate it. The emergence of HIV/AIDS is one of the problems to complete eradication. Recent research has focused on vaccines, diagnostics, and treatment. This review examines vulnerable populations, high-risk groups, and socio-economic factors influencing TBI prevalence. It also explores the intersection of TBI and the COVID-19 pandemic, including healthcare disruptions and transmission dynamics. Advances in TBI diagnosis, biomarkers, prophylactic therapies, and combination treatments are discussed, along with the integration of artificial intelligence (AI) in TBI therapy to optimize treatment and personalize care. Vulnerability to TBI varies based on age, socio-economic status, and immune status. High-risk groups include those with compromised immune systems, the elderly, and those in crowded or poorly ventilated settings. Socioeconomic factors such as poverty and limited healthcare access also contribute to TBI prevalence. The COVID-19 pandemic has disrupted TBI diagnosis and treatment, with limited healthcare access impacting outcomes. Changes in healthcare delivery, like telemedicine, may have long-term impacts on TBI care. Improved biomarkers, like interferon-gamma release assays (IGRAs), offer faster TBI diagnosis. Prophylactic therapies, such as isoniazid preventive therapy (IPT), reduce active TB risk in high-risk groups. Combination treatments are being evaluated for drug-resistant strains. AI integration in TBI therapy could lead to better outcomes by analyzing patient data for personalized treatment plans. In conclusion, TBI remains a global health threat requiring ongoing research and innovative approaches for diagnosis and treatment. Advances in diagnosis, prophylactic therapies, and combination treatments, along with AI integration, offer hope for improved outcomes and better patient care, In conclusion, traumatic brain injury (TBI) persists as a significant global health concern, necessitating sustained research efforts and the development of innovative diagnostic and therapeutic approaches. Advancements in diagnostic methods, prophylactic therapies, combination treatments, and the integration of artificial intelligence hold promise for enhancing outcomes and enhancing patient care.

针对结核分枝杆菌的先进治疗干预措施。
由结核分枝杆菌(M.tb)引起的结核感染(TBI)有或没有活动性结核的临床症状,尽管努力根除它,但仍是一个持续的全球威胁。艾滋病毒/艾滋病的出现是彻底根除的问题之一。最近的研究集中在疫苗、诊断和治疗上。本文综述了易感人群、高危人群和影响TBI患病率的社会经济因素。它还探讨了脑外伤与COVID-19大流行的交集,包括医疗中断和传播动态。讨论了TBI诊断、生物标志物、预防治疗和联合治疗方面的进展,以及人工智能(AI)在TBI治疗中的整合,以优化治疗和个性化护理。对脑外伤的易感性因年龄、社会经济地位和免疫状况而异。高危人群包括免疫系统受损者、老年人以及在拥挤或通风不良环境中的人群。社会经济因素,如贫困和有限的医疗保健机会也有助于TBI的流行。COVID-19大流行扰乱了TBI的诊断和治疗,有限的医疗服务影响了结果。医疗保健服务的变化,如远程医疗,可能对创伤性脑损伤的护理产生长期影响。改进的生物标志物,如干扰素- γ释放测定(IGRAs),提供了更快的TBI诊断。预防性治疗,如异烟肼预防治疗(IPT),可降低高危人群的活动性结核病风险。正在对耐药菌株的联合治疗进行评估。通过分析患者数据,制定个性化治疗计划,将人工智能整合到TBI治疗中,可能会带来更好的结果。总之,创伤性脑损伤仍然是全球健康威胁,需要持续研究和创新的诊断和治疗方法。诊断、预防性治疗和联合治疗方面的进步,以及人工智能的整合,为改善结果和更好的患者护理提供了希望。总之,创伤性脑损伤(TBI)仍然是一个重大的全球健康问题,需要持续的研究努力和创新的诊断和治疗方法的发展。诊断方法、预防治疗、联合治疗以及人工智能的整合等方面的进步,为改善治疗结果和加强患者护理带来了希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Archives of Razi Institute
Archives of Razi Institute Veterinary-Veterinary (all)
CiteScore
1.50
自引率
0.00%
发文量
108
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信